SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: wolfdog2 who wrote (335)1/20/1999 11:41:00 PM
From: aknahow  Respond to of 712
 
The thought was not an original one. It does bear thinking about but I have doubts any of us are privy to enough information about how similar or different the two companies drugs are.



To: wolfdog2 who wrote (335)1/21/1999 1:52:00 AM
From: aknahow  Respond to of 712
 
Info on one of Montsantos produts. Need real audio.

Orbofiban: Oral GP 2b/3a Antagonist in Acute Coronary Syndromes
James Ferguson, Texas Heart Institute
A new oral Glycoprotein 2B-3A inhibitor has been in phase 2 studies in Texas. James Ferguson discussed the results
with Orbofiban in acute co

audiomedica.com



To: wolfdog2 who wrote (335)1/21/1999 4:06:00 PM
From: LLCF  Read Replies (1) | Respond to of 712
 
<George, you've hit the nail on the head. If WS believes that the oral drug can't, won't work, then it follows that in CORR is pouring money down the drain >

Luckily wall street doesn't know beans about biotech!

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News